Abstract
Purpose Dyslipidemia is common in type 2 diabetes (T2D) and contributes to cardiovascular disease (CVD) by exacerbating atherosclerosis and hypercoagulability. Statins can stabilize atherosclerotic plaque and reduce prothrombotic status. In the present study we aimed to evaluate the coagulation activity and the effect of statins on procoagulant state of T2D patients using a novel activated protein C (APC)-dependent thrombin-generation assay. Methods Procoagulant status (by HemosIL ThromboPath (ThP) assay) and in vivo platelet activation (by plasma soluble (s)CD40L levels) were analyzed in a retrospective, cross-sectional study of 198 patients with long-standing T2D and 198 controls. Results Procoagulant status of T2D patients was enhanced when compared to control subjects (p
| Original language | English |
|---|---|
| Pages (from-to) | 301-309 |
| Number of pages | 9 |
| Journal | Cardiovascular Drugs and Therapy |
| Volume | 26 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Aug 2012 |
Fingerprint
Keywords
- Dyslipidemia
- Haemostasis
- Lipid-Lowering Drugs
- Type 2 Diabetes
ASJC Scopus subject areas
- Pharmacology (medical)
- Cardiology and Cardiovascular Medicine
- Pharmacology
Cite this
Impact of statins on the coagulation status of type 2 diabetes patients evaluated by a novel thrombin-generation assay. / Ferroni, P.; Della-Morte, D.; Pileggi, A.; Valente, M. G.; Martini, F.; La Farina, F.; Palmirotta, R.; Meneghini, L. F.; Rundek, T.; Ricordi, C.; Guadagni, F.
In: Cardiovascular Drugs and Therapy, Vol. 26, No. 4, 08.2012, p. 301-309.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Impact of statins on the coagulation status of type 2 diabetes patients evaluated by a novel thrombin-generation assay
AU - Ferroni, P.
AU - Della-Morte, D.
AU - Pileggi, A.
AU - Valente, M. G.
AU - Martini, F.
AU - La Farina, F.
AU - Palmirotta, R.
AU - Meneghini, L. F.
AU - Rundek, T.
AU - Ricordi, C.
AU - Guadagni, F.
PY - 2012/8
Y1 - 2012/8
N2 - Purpose Dyslipidemia is common in type 2 diabetes (T2D) and contributes to cardiovascular disease (CVD) by exacerbating atherosclerosis and hypercoagulability. Statins can stabilize atherosclerotic plaque and reduce prothrombotic status. In the present study we aimed to evaluate the coagulation activity and the effect of statins on procoagulant state of T2D patients using a novel activated protein C (APC)-dependent thrombin-generation assay. Methods Procoagulant status (by HemosIL ThromboPath (ThP) assay) and in vivo platelet activation (by plasma soluble (s)CD40L levels) were analyzed in a retrospective, cross-sectional study of 198 patients with long-standing T2D and 198 controls. Results Procoagulant status of T2D patients was enhanced when compared to control subjects (p
AB - Purpose Dyslipidemia is common in type 2 diabetes (T2D) and contributes to cardiovascular disease (CVD) by exacerbating atherosclerosis and hypercoagulability. Statins can stabilize atherosclerotic plaque and reduce prothrombotic status. In the present study we aimed to evaluate the coagulation activity and the effect of statins on procoagulant state of T2D patients using a novel activated protein C (APC)-dependent thrombin-generation assay. Methods Procoagulant status (by HemosIL ThromboPath (ThP) assay) and in vivo platelet activation (by plasma soluble (s)CD40L levels) were analyzed in a retrospective, cross-sectional study of 198 patients with long-standing T2D and 198 controls. Results Procoagulant status of T2D patients was enhanced when compared to control subjects (p
KW - Dyslipidemia
KW - Haemostasis
KW - Lipid-Lowering Drugs
KW - Type 2 Diabetes
UR - http://www.scopus.com/inward/record.url?scp=84864464224&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84864464224&partnerID=8YFLogxK
U2 - 10.1007/s10557-012-6388-y
DO - 10.1007/s10557-012-6388-y
M3 - Article
C2 - 22527619
AN - SCOPUS:84864464224
VL - 26
SP - 301
EP - 309
JO - Cardiovascular Drugs and Therapy
JF - Cardiovascular Drugs and Therapy
SN - 0920-3206
IS - 4
ER -